Cover Image
市場調查報告書

全球公共醫療相關的聯盟條件、契約

Global Public Health Partnering 2010-2016: Deal trends, players and financials

出版商 Current Partnering, a division of Wildwood Ventures Limited 商品編碼 263938
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
全球公共醫療相關的聯盟條件、契約 Global Public Health Partnering 2010-2016: Deal trends, players and financials
出版日期: 2016年09月01日 內容資訊: 英文
簡介

本報告提供全球公共醫療相關市場上企業聯盟的締結趨勢與其內容(聯盟條件)相關分析、近幾年的企業聯盟/交易形成情形與特徵(各類型、開發階段、適應症)、平均交易條件、代表性資本交易的概要、大醫藥品企業趨勢、近幾年的聯盟交易一覽與其明細等資訊彙整,為您概述為以下內容。

摘要整理

第1章 簡介

第2章 公共醫療相關的交易形成趨勢

  • 簡介
  • 過去數年的公共醫療相關的聯盟趨勢
  • 大型製藥企業的公共醫療相關的交易形成活動
  • 沒參加公共醫療相關交易的大型製藥企業
  • 公共醫療相關的聯盟:各交易類型
  • 公共醫療相關的聯盟:各產業領域
  • 公共醫療相關的聯盟:各開發階段
  • 公共醫療相關的聯盟:各技術種類
  • 公共醫療相關的聯盟:各適應症
  • 公共醫療相關的聯盟的平均交易條件
    • 交易總額 (headline values)
    • 預付款金
    • 階段性付款
    • 權利金費率

第3章 代表性公共醫療相關的資本交易

  • 簡介
  • 代表性資本交易:各金額
  • 代表性資本交易:大型製藥企業有關的東西

第4章 大型製藥企業的公共醫療相關的資本交易

  • 簡介
  • 與大型製藥企業合作交易的有效利用方法
  • 大型製藥企業各公司簡介(共31公司)

第5章 公共醫療相關的聯盟契約一覽

  • 簡介
  • 各交易類型
  • 開發、臨床實驗的各階段
  • 各技術種類一覽

第6章 各治療標靶的交易形成

  • 簡介
  • 各治療標靶的資本交易
    • 公共醫療
    • 吸煙成癮症
    • 毒品中毒
    • 酒精中毒
    • 肥胖
    • 醫療教育
    • 預防醫療

第7章 聯盟資源中心

  • 線上聯盟
  • 聯盟相關活動
  • 相關調查

附錄

  • 附錄1 公共醫療相關的資本交易的一覽:各企業名(A∼Z),總計7年份
  • 附錄2 公共醫療相關的資本交易的一覽:各交易類型,總計7年份
  • 附錄3 公共醫療相關的資本交易的一覽:各開發階段,總計7年份
  • 附錄4 公共醫療相關的資本交易的一覽:各技術種類,總計7年份
  • 附錄5 資本交易的種類

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: CP2222

‘Global Public Health Partnering 2010-2016: Deal trends, players and financials’ provides comprehensive understanding and unprecedented access to the public health partnering deals and agreements entered into by the worlds leading healthcare companies

‘Global Public Health Partnering 2010 to 2016’ provides the full collection of Public Health disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

  • Trends in Public Health partnering deals
  • Financial deal terms for headline, upfront and royalty by stage of development
  • Public Health partnering agreement structure
  • Public Health partnering contract documents
  • Top Public Health deals by value
  • Most active Public Health dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Public Health disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Public Health deals.

The report presents financial deal terms values for Public Health deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Public Health dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Public Health dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Public Health deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Public Health dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Public Health deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Public Health partnering deals by specific Public Health target announced since 2010. The chapter is organized by specific Public Health therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Public Health partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Public Health partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Public Health technologies and products.

Report scope

‘Global Public Health Partnering 2010 to 2016’ is intended to provide the reader with an in-depth understanding and access to Public Health trends and structure of deals entered into by leading companies worldwide.

‘Global Public Health Partnering 2010 to 2016’ includes:

  • Trends in Public Health dealmaking in the biopharma industry since 2010
  • Analysis of Public Health deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of Public Health deal contract documents
  • Comprehensive access to over 3500 Public Health deal records
  • The leading Public Health deals by value since 2010
  • Most active Public Health dealmakers since 2010

The report includes deals for the following indications: Addiction, Smoking, Drugs, Alcohol, Health education, Obesity, Preventative medicine, plus other public health indications.

In ‘Global Public Health Partnering 2010 to 2016’, available deals and contracts are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The ‘Global Public Health Partnering 2010-2016’ report provides comprehensive access to available deals and contract documents for over 200 public health deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are the sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

‘Global Public Health Partnering 2010 to 2016’ provides the reader with the following key benefits:

  • In-depth understanding of Public Health deal trends since 2010
  • Access Public Health deal headline, upfront, milestone and royalty data
  • Research hundreds of actual contracts between Public Health partner companies
  • Comprehensive access to over 750 links to actual Public Health deals entered into by the world's biopharma companies
  • Indepth review of Public Health deals entered into by the top 25 most active dealmakers
  • Benchmark the key deal terms companies have agreed in previous deals
  • Identify key terms under which companies partner Public Health opportunities
  • Uncover companies actively partnering Public Health opportunities

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Public Health dealmaking

  • 2.1. Introduction
  • 2.2. Public Health partnering over the years
  • 2.3. Public Health partnering by deal type
  • 2.4. Public Health partnering by industry sector
  • 2.5. Public Health partnering by stage of development
  • 2.6. Public Health partnering by technology type
  • 2.7. Public Health partnering by therapeutic indication

Chapter 3 -Financial deal terms for Public Health partnering

  • 3.1. Introduction
  • 3.2. Disclosed financials terms for Public Health partnering
  • 3.3. Public Health partnering headline values
  • 3.4. Public Health deal upfront payments
  • 3.5. Public Health deal milestone payments
  • 3.6. Public Health royalty rates

Chapter 4 - Leading Public Health deals and dealmakers

  • 4.1. Introduction
  • 4.2. Most active in Public Health partnering
  • 4.3. List of most active dealmakers in Public Health
  • 4.4. Top Public Health deals by value

Chapter 5 - Public Health contract document directory

  • 5.1. Introduction
  • 5.2. Public Health partnering deals where contract document available

Chapter 6 - Public Health dealmaking by therapeutic target

  • 6.1. Introduction
  • 6.2. Deals by Public Health therapeutic target

Appendices

  • Appendix 1 - Directory of Public Health deals by company A-Z 2010 to 2016
  • Appendix 2 - Directory of Public Health deals by deal type 2010 to 2016
  • Appendix 3 - Directory of Public Health deals by stage of development 2010 to 2016
  • Appendix 4 - Directory of Public Health deals by technology type 2010 to 2016
  • Further reading on dealmaking
  • Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from CurrentPartnering

Table of figures

  • Figure 1: Public Health partnering since 2010
  • Figure 2: Public Health partnering by deal type since 2010
  • Figure 3: Public Health partnering by industry sector since 2010
  • Figure 4: Public Health partnering by stage of development since 2010
  • Figure 5: Public Health partnering by technology type since 2010
  • Figure 6: Public Health partnering by indication since 2010
  • Figure 7: Public Health deals with a headline value
  • Figure 8: Public Health deals with upfront payment values
  • Figure 9: Public Health deals with milestone payment
  • Figure 10: Public Health deals with royalty rates
  • Figure 11: Active Public Health dealmaking activity- 2010 to 2016
  • Figure 12: Top Public Health deals by value since 2010
Back to Top